Chai Discovery closed a $130 million Series B to expand commercialization and R&D of Chai‑2, its generative AI platform for de novo antibody design. The company reported preprints showing double‑digit success rates in zero‑shot design experiments and later data claiming high developability for full‑length therapeutic mAbs designed in silico. Chai says Chai‑2 delivers atomistic accuracy and rapid cycles from design to wet‑lab validation, which the company argues will compress preclinical timelines. The funding will grow engineering, wet‑lab validation and commercial partnerships. Investors have signaled strong interest in AI‑first biologics discovery; the round underscores a broader trend toward computationally generated therapeutic molecules and closer coupling of AI models with experimental pipelines.